Other News To Note
Tuesday, July 19, 2011
Transcept Pharmaceuticals Inc., of Point Richmond, Calif., is eliminating approximately 45 percent of its work force as it looks to conserve cash following the receipt of its second complete response letter from the FDA for insomnia drug Intermezzo (zolpidem tartrate sublingual tablet).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.